Skip to main content
logo
Innate Pharma S.A. (EPA:IPH)
France flag France · Delayed Price · Currency is EUR
1.162
+0.038 (3.38%)
At close: Apr 2, 2026

Innate Pharma Cash Flow Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-49.18-49.47-7.57-58.1-52.81
Depreciation & Amortization
1.381.995.094.414.6
Loss (Gain) From Sale of Assets
0.020.02-0.52--0.37
Asset Writedown & Restructuring Costs
---41-
Loss (Gain) From Sale of Investments
0.56-1.34-1.591.37-0.99
Stock-Based Compensation
2.573.944.264.252.62
Other Operating Activities
2.52-1.21-0.130.43-1.62
Change in Accounts Receivable
-51.81-13.67--
Change in Accounts Payable
--1.01-3.89--
Change in Unearned Revenue
--7.04-4--
Change in Other Net Operating Assets
-10.63-4.11-10.54-12.5-9.89
Operating Cash Flow
-52.76-6.9-32.56-19.16-58.46
Capital Expenditures
-0.14-0.39-0.35-0.54-0.93
Sale of Property, Plant & Equipment
--0.15-0.01
Sale (Purchase) of Intangibles
---2-0.59-0.4
Investment in Securities
7.049.5922.773-
Other Investing Activities
0.3900.06-00.41
Investing Cash Flow
7.299.220.631.88-0.92
Long-Term Debt Issued
----28.7
Long-Term Debt Repaid
-8.91-8.94-2.36-2.03-2.07
Net Debt Issued (Repaid)
-8.91-8.94-2.36-2.0326.63
Issuance of Common Stock
14.982.930.40.20.5
Other Financing Activities
-----0.31
Financing Cash Flow
6.07-6.01-1.97-1.8326.82
Foreign Exchange Rate Adjustments
1.09-0.510.27-0.43-0.48
Miscellaneous Cash Flow Adjustments
--00-0
Net Cash Flow
-38.3-4.21-13.62-19.53-33.04
Free Cash Flow
-52.9-7.29-32.91-19.69-59.39
Free Cash Flow Margin
-587.40%-36.22%-53.39%-34.14%-240.40%
Free Cash Flow Per Share
-0.59-0.09-0.41-0.25-0.75
Cash Interest Paid
----0.31
Levered Free Cash Flow
-33.817.12-27.07-32.74-15.02
Unlevered Free Cash Flow
-33.817.47-26.67-32.56-14.82
Change in Working Capital
-10.6339.16-32.09-12.5-9.89
Source: S&P Global Market Intelligence. Standard template. Financial Sources.